[go: up one dir, main page]

BR9913698A - Peptìdeo sinalizador de enterotoxina ii de e. coli modificado e um microorganismo expressando uma proteìna de fusão do peptìdeo e uma proteìna heteróloga - Google Patents

Peptìdeo sinalizador de enterotoxina ii de e. coli modificado e um microorganismo expressando uma proteìna de fusão do peptìdeo e uma proteìna heteróloga

Info

Publication number
BR9913698A
BR9913698A BR9913698-8A BR9913698A BR9913698A BR 9913698 A BR9913698 A BR 9913698A BR 9913698 A BR9913698 A BR 9913698A BR 9913698 A BR9913698 A BR 9913698A
Authority
BR
Brazil
Prior art keywords
peptide
modified
protein
heterologous protein
enterotoxin
Prior art date
Application number
BR9913698-8A
Other languages
English (en)
Other versions
BRPI9913698B1 (pt
Inventor
Se Chang Kwon
Sung Youb Jung
Hoon Shin
Ki Doo Choi
Gwan Sun Lee
Jay Do Choi
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR9913698A publication Critical patent/BR9913698A/pt
Publication of BRPI9913698B1 publication Critical patent/BRPI9913698B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"PEPTìDEO SINALIZADOR DE ENTEROTOXINA II DE E.COLI MODIFICADO E UM MICROORGANISMO EXPRESSANDO UMA PROTEìNA DE FUSãO DO PEPTìDEO E UMA PROTEìNA HETERóLOGA". Uma proteina heteróloga é produzida por: (i) cultivo de um microorganismo transformado com um vetor de expressão compreendendo um gene codificando um peptídeo sinalizador de enterotoxina II de B.coli modificado, fundido à proteína heteróloga para produzir e secretar a proteína heteróloga para periplasma, o peptídeo sinalizador de enterotoxina II de B.coli modificado é obtido por substituição de pelo menos um dos segundo, quarto, quinto, décimo segundo, vigésimo e vigésimo segundo aminoácidos do peptídeo sinalizador de enterotoxina II de B.coli da seguinte seq³ência de aminoácido (SRQ ID NO: 1) com outro aminoácido, contanto que, pelo menos um dos segundo e quarto aminoácidos do peptídeo modificado seja lisina; e (ii) recuperando a proteína heteróloga do periplasma.
BRPI9913698A 1998-09-15 1999-09-15 peptídeo sinalizador de enterotoxina ii de e. coli modificado e um microorganismo expressando uma proteína de fusão do peptídeo e uma proteína heteróloga BRPI9913698B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019980038061A KR100316347B1 (ko) 1998-09-15 1998-09-15 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
PCT/KR1999/000547 WO2000015661A1 (en) 1998-09-15 1999-09-15 Modified e. coli enterotoxin ii signal peptide and a microorganism expressing a fusion protein of said peptide and a heterologous protein

Publications (2)

Publication Number Publication Date
BR9913698A true BR9913698A (pt) 2002-01-29
BRPI9913698B1 BRPI9913698B1 (pt) 2016-06-21

Family

ID=36120918

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9913698A BRPI9913698B1 (pt) 1998-09-15 1999-09-15 peptídeo sinalizador de enterotoxina ii de e. coli modificado e um microorganismo expressando uma proteína de fusão do peptídeo e uma proteína heteróloga

Country Status (14)

Country Link
US (1) US6605697B1 (pt)
EP (1) EP1114062B1 (pt)
JP (1) JP3701201B2 (pt)
KR (1) KR100316347B1 (pt)
CN (1) CN1144815C (pt)
AT (1) ATE317398T1 (pt)
AU (1) AU754435B2 (pt)
BR (1) BRPI9913698B1 (pt)
CA (1) CA2342537C (pt)
DE (1) DE69929805T2 (pt)
DK (1) DK1114062T3 (pt)
NZ (1) NZ510385A (pt)
RU (1) RU2198179C2 (pt)
WO (1) WO2000015661A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242177B1 (en) * 1995-03-01 2001-06-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
KR100356140B1 (ko) 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
KR100360594B1 (ko) * 2000-01-19 2002-11-13 한미약품공업 주식회사 인간 인터페론 알파의 발현 분비벡터 및 이를 이용한인터페론 알파의 생산 방법
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
MXPA05007210A (es) 2003-11-13 2006-02-10 Hanmi Pharm Ind Co Ltd Complejo de proteina que usa un fragmento de inmunoglobulina y metodo para la preparacion del mismo.
EP2049148B1 (en) 2006-07-06 2016-09-28 Daewoong Co., Ltd. A stable liquid formulation of human growth hormone
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
KR101831300B1 (ko) 2010-10-29 2018-02-23 한미사이언스 주식회사 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EA037848B1 (ru) 2016-07-14 2021-05-27 Общество С Ограниченной Ответственностью "Биохимический Агент" Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты)
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2020185632A1 (en) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
JP2022537670A (ja) 2019-06-12 2022-08-29 オブシディアン セラピューティクス， インコーポレイテッド Ｃａ２の組成物および調整可能な制御方法
US20220267398A1 (en) 2019-06-12 2022-08-25 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
MX2023006704A (es) 2020-12-15 2023-06-20 Arvada Therapeutics Inc Composiciones dsg2 y metodos para el tratamiento de covid-19.
AR127555A1 (es) 2021-11-02 2024-02-07 Arvada Therapeutics Inc Composiciones y métodos que comprenden dsg2 asociados a enfermedades cardíacas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308835A (en) * 1984-07-09 1994-05-03 Praxis Biologics, Inc. Production of the E. coli LT-B enterotoxin subunit
DE3586386T2 (de) * 1984-10-05 1993-01-14 Genentech Inc Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung.
JPS63230089A (ja) * 1987-03-18 1988-09-26 Takeda Chem Ind Ltd 分泌発現による蛋白質の製造法
JPH0479898A (ja) * 1990-07-23 1992-03-13 Kitasato Inst:The コレラ菌及び毒素原性大腸菌を同時検出するためのｄｎａ及びｒｎａプローブとそれらを用いたコレラ菌及び毒素原性大腸菌の検出方法
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon

Also Published As

Publication number Publication date
WO2000015661A1 (en) 2000-03-23
CA2342537C (en) 2008-07-08
EP1114062A1 (en) 2001-07-11
EP1114062B1 (en) 2006-02-08
CA2342537A1 (en) 2000-03-23
ATE317398T1 (de) 2006-02-15
DK1114062T3 (da) 2006-06-06
JP2002538765A (ja) 2002-11-19
JP3701201B2 (ja) 2005-09-28
NZ510385A (en) 2002-12-20
DE69929805D1 (de) 2006-04-20
US6605697B1 (en) 2003-08-12
BRPI9913698B1 (pt) 2016-06-21
RU2198179C2 (ru) 2003-02-10
CN1318070A (zh) 2001-10-17
DE69929805T2 (de) 2006-10-26
KR20000019788A (ko) 2000-04-15
CN1144815C (zh) 2004-04-07
AU5761899A (en) 2000-04-03
KR100316347B1 (ko) 2002-08-27
AU754435B2 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
BR9913698A (pt) Peptìdeo sinalizador de enterotoxina ii de e. coli modificado e um microorganismo expressando uma proteìna de fusão do peptìdeo e uma proteìna heteróloga
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
GB0121591D0 (en) Hybrid and tandem expression of neisserial proteins
DK105489D0 (da) Polypeptid
ATE391181T1 (de) Bioaktive il-12 fusionsproteine
KR960031602A (ko) 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조 방법
BR9506733A (pt) Proteina de fusão de hematopoiese il-3 multivarian
KR970707153A (ko) 카텝신 02 프로테아제(cathepsin 02 protease)
SE9100799D0 (sv) Recombinant human factor viii derivatives
AU1550297A (en) Amino acid-enriched plant protein reserves, particularly lysine-enriched maize gamma-zein, and plants expressing such proteins
DK0532587T3 (da) Fremgangsmåder til trans-destabilisering af specifikke proteiner in vivo
ZA8860B (en) Pancreatic secretory trypsin inhibitor and variants thereof produced by a recombinant host,process,expression vector and recombinant host therefor and pharmaceutical use thereof
ATE248918T1 (de) Rekombinante dnase b aus streptococcus pyogenes
NO971621L (no) Keratinocyttvekstfaktoranaloger
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
PT635025E (pt) Processo para preparar proteinas modificadas
ITMI930456A1 (it) Vettore ricombinante e suo impiego per la preparazione esocellulare di anticorpi in forma di singola molecola da bacillus subtilis
DK0794255T3 (da) Fremgangsmåde til spaltning af kimært protein ved anvendelse af processeringsenzym
KR930000684A (ko) 클로닝된 글루탐산 탈탄산효소
PT98332A (pt) Metodo para a producao de uma proteina biologicamente activa por processamento in vitro de proteinas de fusao
ATE141947T1 (de) Klonierung eines neuen mitgliedes der familie der fibroblasten-wachstumsfaktoren (fgf)-rezeptoren
ES2158235T3 (es) Peptidos antigenicos con substituciones de glicina.
DK0572088T3 (da) Modificerede signalsekvenser
AU654155B2 (en) A DNA encoding a protein which binds to the enhancer of alpha-fetoprotein gene
UY25951A1 (es) Polipéptidos receptores p75 (tipo ii) de factor de necrosis tumoral purificados

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: HANMI HOLDINGS CO., LTD. (KR)

Free format text: TRANSFERIDO DE: HANMI PHARM. CO., LTD.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HANMI SCIENCE CO., LTD. (US)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/06/2016, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24D Patent annual fee: restoration after fee payment
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.